Pfizer, BioNTech initiate rolling submission of BLA for COVID-19 vaccine

By The Science Advisory Board staff writers

May 7, 2021 -- Pfizer and BioNTech announced on Friday that they have started a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of their messenger RNA (mRNA) vaccine to prevent COVID-19 in individuals ages 16 years and older.

The vaccine is currently available in the U.S. under an emergency use authorization (EUA) granted by the FDA on December 11, 2020. The BLA is supported by analyses from phase III clinical results, where the vaccine's efficacy and safety were observed up to six months after the second dose.

Pfizer and BioNTech also have submitted an application to expand the current EUA for their COVID-19 vaccine to include individuals 12 to 15 years of age. The companies intend to submit a supplemental BLA to support licensure of the vaccine in this age group once the required data six months after the second vaccine dose are available.

Pfizer, BioNTech submit expanded CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday they have submitted a variation to the conditional marketing authorization (CMA) for use of their COVID-19 vaccine...
Pfizer, BioNTech confirm high efficacy of COVID-19 vaccine up to 6 months
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine is 91.3% effective against the virus six days through up to six months after the second dose, according to...
Pfizer starts evaluation of SARS-CoV-2 oral antiviral
Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and...
Pyxis licenses 2 oncology ADC programs from Pfizer
Pyxis Oncology has entered into a worldwide license agreement with Pfizer for the development and commercialization of two antibody-drug conjugate (ADC)...
Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine
Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter